DK3003397T3 - Gelformuleringer til styring af radioterapi - Google Patents

Gelformuleringer til styring af radioterapi Download PDF

Info

Publication number
DK3003397T3
DK3003397T3 DK14726350.3T DK14726350T DK3003397T3 DK 3003397 T3 DK3003397 T3 DK 3003397T3 DK 14726350 T DK14726350 T DK 14726350T DK 3003397 T3 DK3003397 T3 DK 3003397T3
Authority
DK
Denmark
Prior art keywords
gel formulations
therapy control
radio therapy
radio
control
Prior art date
Application number
DK14726350.3T
Other languages
English (en)
Inventor
Morten Albrechtsen
Thomas Lars Andresen
Rasmus Irming Jølck
Original Assignee
Nanovi Radiotherapy A P S
Univ Danmarks Tekniske
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanovi Radiotherapy A P S, Univ Danmarks Tekniske filed Critical Nanovi Radiotherapy A P S
Application granted granted Critical
Publication of DK3003397T3 publication Critical patent/DK3003397T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0442—Polymeric X-ray contrast-enhancing agent comprising a halogenated group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0457—Semi-solid forms, ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14726350.3T 2013-05-24 2014-05-23 Gelformuleringer til styring af radioterapi DK3003397T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350637 2013-05-24
PCT/EP2014/060673 WO2014187962A1 (en) 2013-05-24 2014-05-23 Gel formulations for guiding radiotherapy

Publications (1)

Publication Number Publication Date
DK3003397T3 true DK3003397T3 (da) 2020-11-16

Family

ID=50819731

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14726350.3T DK3003397T3 (da) 2013-05-24 2014-05-23 Gelformuleringer til styring af radioterapi

Country Status (15)

Country Link
US (2) US10561746B2 (da)
EP (1) EP3003397B1 (da)
JP (1) JP6537498B2 (da)
KR (1) KR102242406B1 (da)
CN (1) CN105407927B (da)
AU (1) AU2014270358B2 (da)
BR (1) BR112015029144A2 (da)
CA (1) CA2913100C (da)
DK (1) DK3003397T3 (da)
ES (1) ES2828752T3 (da)
HK (1) HK1223545A1 (da)
IL (1) IL242676B (da)
MX (1) MX2015016155A (da)
RU (1) RU2703303C2 (da)
WO (1) WO2014187962A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6537498B2 (ja) 2013-05-24 2019-07-03 ダンマークス テクニスケ ウニバーシテート 撮像造影用組成物及びキット
WO2016079331A1 (en) * 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for enhancing the effect of radiotherapy
CN104645356B (zh) * 2015-01-30 2018-11-13 复旦大学 一类x射线显影的热致水凝胶及其制备方法
MX2018014087A (es) * 2016-05-20 2019-06-10 Univ Denmark Tech Dtu Composicion de marcaje palpable.
WO2018215595A1 (en) 2017-05-24 2018-11-29 Technical University Of Denmark Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility
US11124630B2 (en) * 2017-06-04 2021-09-21 Technion Research & Development Foundation Limited Inverse-freezing compositions and use thereof
IL257226B2 (en) * 2018-01-29 2023-04-01 Technion Res & Development Found Ltd Compounds characterized by an inverse freezing property and their uses
US20210275692A1 (en) * 2018-06-19 2021-09-09 Danmarks Tekniske Universitet Solution comprising fluorescent dye as fiducial marker
WO2019243419A1 (en) * 2018-06-19 2019-12-26 Danmarks Tekniske Universitet Brachygel for treatment of cancer and/or for guidance of surgery
WO2020227107A1 (en) * 2019-05-03 2020-11-12 Palette Life Sciences, Inc. Improved tissue spacers
CA3143104A1 (en) * 2019-06-12 2020-12-17 Technical University Of Denmark Dissacharide formulations for controlled drug release
KR102323957B1 (ko) * 2019-07-26 2021-11-08 경북대학교 산학협력단 모든 자기공명영상촬영 및 전산화단층촬영 용 영상 마커 및 이의 제조 방법
WO2021102241A1 (en) * 2019-11-20 2021-05-27 The Regents Of The University Of California Liquid embolic material composition
CN111228215A (zh) * 2020-03-09 2020-06-05 王岩松 一种自组装可成像丝素蛋白水凝胶的制备方法
CN111632142B (zh) * 2020-06-24 2022-08-23 南方科技大学 一种基于x射线响应的药物释放系统及其制备方法和应用
CN112279945B (zh) * 2020-10-13 2022-05-27 青岛科技大学 一种感温变色水凝胶型智能视窗及其制备方法、产品与应用
CN114652862A (zh) * 2020-12-23 2022-06-24 成都纽瑞特医疗科技股份有限公司 一种放射性树脂微球注射剂及制备方法和用途
AU2021414121A1 (en) * 2020-12-29 2023-06-29 Suzhou Xinxin Biopharma Co., Ltd Compositions and associated methods for sustained-release of radioactive agents and their applications
US11672875B2 (en) * 2021-03-17 2023-06-13 Saint Louis University Nanoparticle-alginate gels for X-ray imaging of the vasculature
CN115282127B (zh) * 2022-04-21 2023-08-29 广州医科大学附属第二医院 壳聚糖海藻酸钙纳米粒微球及其制备方法
US20240207456A1 (en) * 2022-06-16 2024-06-27 Theragenics Corporation Photocurable compositions and methods for delivering radiation to a subject
CN115678048B (zh) * 2022-11-27 2024-05-31 福州大学 一种可促进创面愈合并减少疤痕形成的可注射复合水凝胶及其制备方法和应用
CN116251201B (zh) * 2023-04-03 2024-04-05 无锡市第二人民医院 抗类风湿性关节炎的自组装水凝胶及其制备方法与应用
US20240335568A1 (en) * 2023-04-07 2024-10-10 Boston Scientific Scimed, Inc. Radiopaque polysaccharide hydrogels and methods of making the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE403255B (sv) 1972-09-19 1978-08-07 Pharmacia Ab Rontgenkontrastmedel i vilket ett rontgenkontrastgivande emne utgores av en polymer i vilken ingar jodsubstituerade aromatiska grupper
US5562099A (en) 1990-10-05 1996-10-08 Massachusetts Institute Of Technology Polymeric microparticles containing agents for imaging
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
DE69634277T2 (de) 1995-06-07 2006-01-05 Southern Biosystems, Inc., Birmingham Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
CA2327816A1 (en) * 1998-04-09 1999-10-21 Nycomed Imaging As Use of particulate contrast agents in diagnostic imaging for studying physiological parameters
SE522098C2 (sv) 2001-12-20 2004-01-13 Bone Support Ab Ett nytt benmineralsubstitut
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
JP3755880B2 (ja) * 2003-06-11 2006-03-15 日本航空電子工業株式会社 コネクタ
US7790141B2 (en) 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
AU2005287175B2 (en) * 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
WO2006124021A1 (en) * 2005-05-12 2006-11-23 Angiotech International Ag Compositions and methods for treating diverticular disease
CN103071209A (zh) * 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
US20090026345A1 (en) * 2007-07-24 2009-01-29 Tracy Mark S Electronic device shock-absorbing mounting system
EP2399610A3 (en) 2007-09-24 2012-09-05 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
WO2009049089A1 (en) 2007-10-09 2009-04-16 Washington University In St. Louis Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
WO2009073193A2 (en) 2007-12-03 2009-06-11 The Johns Hopkins University Methods of synthesis and use of chemospheres
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
EP3960215B1 (en) * 2009-12-15 2024-10-16 Incept, LLC Implants and biodegradable fiducial markers
CN103079642A (zh) * 2010-07-16 2013-05-01 丹麦科技大学 纳米颗粒引导的放射疗法
US20120039814A1 (en) 2010-08-13 2012-02-16 Sample Jennifer L Topical Compositions and Methods of Detection and Treatment
US20120065614A1 (en) 2010-09-10 2012-03-15 University Of North Texas Polyionic transitional metal phosphorescent complex/polymer hybrid systems for bioimaging and sensing applications
EP2782603A1 (en) 2011-11-25 2014-10-01 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
JP6537498B2 (ja) 2013-05-24 2019-07-03 ダンマークス テクニスケ ウニバーシテート 撮像造影用組成物及びキット

Also Published As

Publication number Publication date
KR102242406B1 (ko) 2021-04-21
CA2913100C (en) 2021-10-26
KR20160032008A (ko) 2016-03-23
HK1223545A1 (zh) 2017-08-04
CN105407927A (zh) 2016-03-16
US20160089454A1 (en) 2016-03-31
CA2913100A1 (en) 2014-11-27
MX2015016155A (es) 2016-08-19
BR112015029144A2 (pt) 2017-07-25
AU2014270358B2 (en) 2019-01-17
AU2014270358A1 (en) 2015-12-03
RU2703303C2 (ru) 2019-10-16
IL242676B (en) 2018-07-31
EP3003397A1 (en) 2016-04-13
US10561746B2 (en) 2020-02-18
RU2015154681A (ru) 2017-06-30
WO2014187962A1 (en) 2014-11-27
ES2828752T3 (es) 2021-05-27
JP2016519154A (ja) 2016-06-30
JP6537498B2 (ja) 2019-07-03
NZ714077A (en) 2020-12-18
CN105407927B (zh) 2020-03-20
EP3003397B1 (en) 2020-08-19
US20200197541A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
DK3003397T3 (da) Gelformuleringer til styring af radioterapi
DK2999103T3 (da) Konverter og fremgangsmåde til styring deraf
DK2996556T3 (da) System til billedstyret procedure
DK3082926T3 (da) Forbindelser til befugtningssystem
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3603794T3 (da) Fremgangsmåde til overflader med gelmønster
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK3544364T3 (da) Indretninger til radioforbindelser
DK2973896T3 (da) Fasearrangeret styring til laserstrålepositioneringssystemer
DK3013544T3 (da) Fremgangsmåde til betonfremstilling
DK3404106T3 (da) Ekspressionssystem til selektiv genterapi
BR302013003401S1 (pt) Configuração aplicada em bolsa
CL2013001253S1 (es) Unidad de control
DK2764881T3 (da) System til medicinsk behandling
DK2992104T3 (da) Fremgangsmåde til ekspression
DK2767269T3 (da) Terapeutisk anordning
DK3089749T3 (da) Kombinerede præparater til behandling af cancer
CL2016001382A1 (es) Estabilidad de gel mejorada
DE112014003026A5 (de) Steuergerät
DK3052102T3 (da) Sammensætninger til behandling af cancere
GB2516089B (en) Supplementary Services Management Setting Control
DK3007704T3 (da) Kombinationsterapi til akromegali
DK2752606T3 (da) Kanalsystem
DK3082860T3 (da) Fremgangsmåde til behandling af sår